Lantheus Holdings, Inc. $LNTH Holdings Decreased by Algert Global LLC

Key Points

• Algert Global LLC has reduced its holdings in Lantheus Holdings, Inc. by 51.7%, now owning only 10,301 shares valued at approximately $1 million.
• In contrast, several institutional investors like Janus Henderson Group and Farallon Capital Management significantly increased their stakes in Lantheus, reflecting varied investor confidence.
• Lantheus reported a quarterly EPS of $1.57, falling short of market estimates, alongside a year-over-year revenue decline of 4.1% to $378.05 million.

Algert Global LLC reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 51.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,301 shares of the medical equipment provider's stock after selling 11,040 shares during the period. Algert Global LLC's holdings in Lantheus were worth $1,005,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Signaturefd LLC lifted its stake in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 116 shares in the last quarter. Hughes Financial Services LLC acquired a new position in shares of Lantheus in the 1st quarter valued at approximately $81,000. UMB Bank n.a. boosted its stake in shares of Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares during the last quarter. Blue Trust Inc. grew its position in shares of Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after buying an additional 633 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Lantheus by 29.3% in the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after buying an additional 298 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

NASDAQ:LNTH traded down $0.92 during midday trading on Thursday, reaching $55.93. 272,207 shares of the company traded hands, compared to its average volume of 1,201,445. The firm has a market capitalization of $3.80 billion, a price-to-earnings ratio of 14.86 and a beta of 0.14. The company has a fifty day moving average price of $70.16 and a 200 day moving average price of $83.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. During the same period in the prior year, the business earned $1.80 earnings per share. Lantheus's quarterly revenue was down 4.1% on a year-over-year basis. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. JMP Securities reduced their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. B. Riley cut their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Finally, William Blair reiterated a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,838,066 shares of company stock worth $384,430,031 in the last ninety days. 1.50% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.